Combined Radiation Therapy and @entity2240 for Preoperative Treatment of Soft Tissue XXXX .

@entity1 @entity137 @entity2240 @entity242 @entity1161 @entity5 @entity39 @entity260 @entity8566 @entity3
BACKGROUND: Antiangiogenic substances and @entity1161 ( @entity1161 ) may have synergistic effects and improve irradiation efficacy. We present a cohort study evaluating the @entity137 of combined @entity2240 and @entity1161 as neoadjuvant treatment of extremity and @entity242 (STS). METHODS: Sixteen @entity1 with locally advanced extremity (6/16) or retroperitoneal (10/16) STS were treated with continuous-dosing @entity2240 (15/16: 37.5  mg daily; 1/16: 25  mg daily) and standard @entity1161 (45-50.4  Gy) preoperatively. Surgery was scheduled 5-9  weeks following neoadjuvant treatment. The primary goal of the study was to determine combined treatment @entity137 according to the Common Terminology Criteria for Adverse Events. Secondary goals were the evaluation of postoperative morbidity and treatment response. RESULTS: Eight of 16 @entity1 developed grade 3, and one @entity1 developed grade 4, hematological @entity137 . One @entity1 experienced grade 3 @entity8566 . The most frequent treatment toxicities of any grade were hematological (15/16) or dermatological (9/16). Three @entity1 had partial response, 11 had stable disease, and 2 had progressive disease according to Response Evaluation Criteria in @entity5 (RECIST). Fourteen of 16 @entity1 underwent surgery; @entity5 were not removed in two @entity1 because of @entity1 refusal or intercurrent @entity3 . The proportion of @entity5 @entity39 exceeded 90  % in 5 of 14 @entity1 , and 4 @entity1 had @entity260 requiring reintervention. CONCLUSIONS: Preoperative treatment with concurrent @entity2240 and @entity1161 was tolerable, and postoperative morbidity did not increase. Combined treatment with @entity1161 and @entity2240 was also feasible in @entity1 with retroperitoneal STS, and warrants further investigation.
